Taiwanese Food and Drug Administration (TFDA) has granted another new drug approval to MICROBIO’s oral drug “Herbiron.” Herbiron is an oral botanical drug combination designed to improve primary dysmenorrhea and iron-deficiency anemia. Human clinical trial has shown that “Herbiron” can significantly alleviate pain associated menstrual cycle discomfort and elevate serum hemoglobin.

“Herbiron” was developed according to international drug development regulations, with comprehensive analysis in preclinical toxicology and pharmacology, and thorough CMC and manufacture standards. The phase III clinical trials was conducted in prestige and respected Taiwanese hospitals (Taipei Veterans General Hospital，Chang Gung Memorial Hospital，Taipei Medical University Hospital，Taiwan Adventist Hospital, Wan Fang Hospital, China Medical University Hospital). The clinical data shows therapeutic efficacy of “Herbiron” significantly alleviate menstrual pain (*p=0.0004) and elevate serum hemoglobin (*p<0.0001).

Reportedly 90 percent of Asian women with active menstrual cycle manifest various degree of discomfort and associated pain. Sixty-four percent of Taiwanese women would choose to use over-the-counter painkiller for their pain management despite the potential side effects such as stomach upsets, ulcers and nausea. Several lines of evidence shows that prolonged use of painkillers (acetaminophen & NSAIDs) can lead to allergic reactions, damages in liver, kidney and stomach, and even lead to cancer.
To help address the pain management for women, starting from November 2014, “Herbiron” is available at local pharmacies.